Zacks Investment Research on MSN2d
FDA Accepts Sanofi's Filing for Multiple Sclerosis Drug Tolebrutinib (Revised)
Sanofi SNY announced that the FDA has accepted its regulatory filing seeking approval for its investigational BTK inhibitor ...
Sanofi gets priority review for its multiple sclerosis treatment by FDA
Sanofi (NASDAQ:SNY) said on Tuesday that the US FDA has granted priority review for the regulatory submission of tolebrutinib ...
Sanofi reports tolebrutinib submission accepted for FDA priority review
The U.S. Food and Drug Administration is evaluating under priority review the regulatory submission of tolebrutinib to treat non-relapsing ...
Contract Pharma1d
Sanofi’s Chlamydia Vaccine Candidate Granted Fast Track Designation by FDA
The FDA has granted fast track designation to Sanofi’s mRNA vaccine candidate for the prevention of chlamydia infection.
MedCity News7d
Sanofi Expands Immunology Prospects, Acquiring Novel Bispecific Drug in $600M Deal
Sanofi is adding a new contender, agreeing to pay $600 million for a bispecific drug with an approach that could be first in class. The sum announced Thursday is an upfront payment for Dren Bio ...
Yahoo Finance2d
FDA Accepts Sanofi's Filing for Multiple Sclerosis Drug Tolebrutinib (Revised)
A similar regulatory filing for the drug is currently under review by the EMA, which is also supported by data from these studies. Per Sanofi, the above results make tolebrutinib the first and the ...
Yahoo Finance3d
FDA Accepts Sanofi's Filing for Multiple Sclerosis Drug Tolebrutinib
A similar regulatory filing for the drug is currently under review by the EMA, which is also supported by data from these studies. Per Sanofi, the above results make tolebrutinib the first and the ...